MedTrace Logo

Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis

NCT02309385 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2017-04-27

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy, safety, and tolerability of dexamethasone sodium phosphate Visulex (DSP-Visulex) after repeated-dose administration in patients with acute anterior uveitis.

Conditions

  • Non-Infectious Anterior Uveitis

Interventions

DRUG

8% Dexamethasone Sodium Phosphate - Visulex

DRUG

15% Dexamethasone Sodium Phosphate - Visulex

DRUG

Prednisolone Acetate (1%) Eye Drops

Sponsors & Collaborators

  • National Eye Institute (NEI)

    collaborator NIH

  • Aciont Inc

    lead OTHER

Principal Investigators

  • William I Higuchi, PhD · Aciont Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2017-03-03
Completion
2017-03-03

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02309385 on ClinicalTrials.gov